The small nucleic acid drug market is booming, projected to reach \$45.5 billion by 2033. Driven by advancements in treating neuromuscular diseases and hATTR amyloidosis, this report analyzes market size, growth, key players (Sarepta, Ionis, Alnylam), and regional trends. Discover the potential and challenges of this rapidly evolving sector.
We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.
